CriticalAntidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative×Serotonin antagonist and reuptake inhibitor (SARI) antidepressant
Updated · Methodology
Mechanism
Trazodone inhibits serotonin reuptake presynaptically and blocks 5-HT2A serotonin receptors postsynaptically (trazodone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label describes it as a selective serotonin reuptake inhibitor (trazodone label, US Food and Drug Administration, FDA). Tranylcypromine irreversibly and non-selectively inhibits monoamine oxidase (MAO) A and B and stops the enzyme from breaking down serotonin, noradrenaline and dopamine (tranylcypromine SmPC, AEMPS). MAO inhibitors impair serotonin metabolism and, together with serotonergic drugs including trazodone, increase the risk of serotonin syndrome (trazodone FDA label). Full MAO activity returns 3–5 days after the last dose of tranylcypromine (tranylcypromine SmPC, AEMPS). According to the US label, MAO inhibition may persist for up to 10 days (tranylcypromine FDA label).
Symptoms
Serotonin syndrome can be life-threatening (trazodone label, US Food and Drug Administration, FDA). It presents with mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (fast heart rate, labile blood pressure, dizziness, sweating, flushing, high body temperature), neuromuscular symptoms (tremor, rigidity, myoclonus, overactive reflexes, poor coordination), seizures, nausea, vomiting or diarrhoea (trazodone FDA label). Fatal serotonin syndrome has been reported, including in people treated with tranylcypromine (tranylcypromine FDA label). The Spanish trazodone summary of product characteristics (SmPC) reports interactions leading to serotonin syndrome or neuroleptic malignant syndrome when trazodone is combined with monoamine oxidase (MAO) inhibitors and other serotonergic drugs (trazodone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The US labels contraindicate the combination. The trazodone label contraindicates trazodone in patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping them, and the tranylcypromine label lists trazodone among contraindicated antidepressants (trazodone and tranylcypromine labels, US Food and Drug Administration, FDA). The Spanish documents are less strict. The trazodone summary of product characteristics (SmPC) does not recommend combining trazodone with MAOIs or starting it during the first 2 weeks after stopping them, although it notes that some doctors prescribe them together (trazodone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The tranylcypromine SmPC does not mention trazodone (tranylcypromine SmPC, AEMPS). Start trazodone no earlier than 14 days after stopping tranylcypromine (trazodone FDA label; trazodone SmPC, AEMPS). When switching from trazodone to tranylcypromine, the US trazodone label requires a gap of at least 14 days (trazodone FDA label). The Spanish trazodone SmPC does not recommend giving an MAOI one week after stopping trazodone (trazodone SmPC, AEMPS), and the Spanish tranylcypromine SmPC recommends a drug-free interval of about 5 half-lives of the previous antidepressant and its active metabolites (tranylcypromine SmPC, AEMPS). If serotonin syndrome develops, stop trazodone and other serotonergic drugs at once and start supportive symptomatic treatment (trazodone FDA label; trazodone SmPC, AEMPS; tranylcypromine FDA label). Treat severe serotonin syndrome caused by an interaction with serotonergic drugs as tranylcypromine poisoning: in intensive care, with close monitoring of pulse, blood pressure, breathing and temperature, and with mechanical ventilation available (tranylcypromine SmPC, AEMPS, overdose section).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Parnate (tranylcypromine) prescribing information (2025)– FDA, DailyMed, Advanz Pharma, setid b72d8187-dfcc-4ea0-b5e9-c0be95b69a27, revised 07/2025, sections 4.1, 5.3, 5.9 and 7.1
- FDA: RALDESY (trazodone hydrochloride) prescribing information (2026)– FDA, DailyMed setid 34708cc1-b0b2-4fd0-b9f3-7f008b457fc9 (Validus), revisión 09/2026 (versión 6), secciones 5.2, 5.3, 5.9 y 7
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.5 (2026)– AEMPS, CIMA, nº registro 88524 (Tranilcipromina Aristo 20 mg comprimidos recubiertos con película; autorizado, no comercializado), revisión 08/2026 (texto revisado 04/2026), secciones 4.2, 4.4, 4.5, 4.8, 4.9 y 5.1
- AEMPS: Ficha técnica: Trazodona, Deprax 100 mg (nº registro 78762), sección 4.5 (2023)– AEMPS, CIMA, nº registro 78762 (Deprax 100 mg comprimidos recubiertos con película, Angelini Pharma España), revisión 11/2023, secciones 4.4, 4.5 y 5.1